Livingston Group Asset Management CO operating as Southport Capital Management acquired a new position in Becton Dickinson and Co (NYSE:BDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,454 shares of the medical instruments supplier’s stock, valued at approximately $525,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Westwood Holdings Group Inc. increased its holdings in Becton Dickinson and by 24.2% in the 2nd quarter. Westwood Holdings Group Inc. now owns 1,056,487 shares of the medical instruments supplier’s stock worth $206,136,000 after acquiring an additional 205,721 shares during the last quarter. Colony Group LLC grew its holdings in Becton Dickinson and by 2.1% during the 2nd quarter. Colony Group LLC now owns 11,889 shares of the medical instruments supplier’s stock valued at $2,320,000 after buying an additional 239 shares in the last quarter. State Street Corp grew its holdings in Becton Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares in the last quarter. Peapack Gladstone Financial Corp grew its holdings in Becton Dickinson and by 1.3% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 36,472 shares of the medical instruments supplier’s stock valued at $7,116,000 after buying an additional 453 shares in the last quarter. Finally, Zions Bancorporation grew its holdings in Becton Dickinson and by 23.7% during the 3rd quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock valued at $2,100,000 after buying an additional 2,050 shares in the last quarter. 75.57% of the stock is owned by institutional investors.

BDX has been the subject of a number of recent analyst reports. Morgan Stanley lifted their target price on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Royal Bank of Canada reaffirmed a “hold” rating and set a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research lowered Becton Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Finally, Wells Fargo & Co reaffirmed a “positive” rating and set a $235.00 target price (up previously from $225.00) on shares of Becton Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $233.80.

Shares of Becton Dickinson and Co (BDX) traded up $2.20 on Tuesday, hitting $236.71. The stock had a trading volume of 1,324,300 shares, compared to its average volume of 1,594,943. The company has a market cap of $53,910.00, a P/E ratio of 50.91, a PEG ratio of 1.79 and a beta of 1.07. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton Dickinson and Co has a 12-month low of $169.19 and a 12-month high of $236.74.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The company’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter last year, the company posted $2.12 EPS. equities research analysts expect that Becton Dickinson and Co will post 10.66 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.27%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 64.52%.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/livingston-group-asset-management-co-operating-as-southport-capital-management-invests-525000-in-becton-dickinson-and-co-bdx-stock/1820060.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.